In the case of global drug research and development being monopolized by European and American chemical pharmaceuticals for a long time, a pharmaceutical company in Tianjin, China, firmly believes that Chinese medicine is a new driving force for the development of new drugs in the future, and strives to explore a combination of the traditional thinking of traditional Chinese medicine and modern pharmaceutical technology. China's characteristics can also be in line with international standards for the development of new drugs.
Powered Roller Conveyor
Powered roller conveyors take less effort to move loads than unpowered (gravity-flow) roller conveyors. They convey items at a controlled speed with even spacing and are typically used in warehousing, manufacturing, package handling, and distribution applications. Each conveyor section consists of rollers that are mounted on a series of axles attached to a frame. A motor-driven belt, chain, or shaft turns the rollers, so these conveyors do not require a manual push or slope to move loads down the line. The rollers provide a stable surface for moving loads with rimmed or uneven bottoms, such as drums, pails, pallets, skids, and bags. Loads roll forward along the conveyor, and they can be pushed from side to side across the width of the conveyor. The conveyor's roller spacing density affects the size of the items that can be conveyed on it. The smallest item on the conveyor should be supported by at least three rollers at all times.
Drum Roller Conveyor,Powered Roller Conveyor,Telescopic Roller Conveyor,Powered Roller Conveyor System Foshan Heiteng Intelligent Technology Co., Ltd , https://www.heitengproductionline.com
"Component Chinese medicine" is a new concept put forward by Yan Xijun, president of the Tianshi Group, at the World Congress of Traditional Medicine held in Beijing on the 8th, and it is also the "breach" of traditional Chinese medicine that this state-level innovative enterprise has explored after six years of practice.
Yan Xijun said that the development of "component Chinese medicine" is based on the original prescription of traditional Chinese medicine, using modern techniques to isolate the effective components of traditional Chinese medicine, clarifying the synergistic effects of various components, ensuring the homogeneity of the active ingredients and establishing pharmaceutical standards. At the same time, the company can also select effective ingredients to form a new drug without any impurities under the guidance of TCM principle of differentiation and treatment, so that its targeted and treatment accuracy is greatly improved.
At present, the nation's first herbal component library has been established in the Tianshili Group. The researchers prepared 10,661 components and 235 compounds from 282 medicinal herbs and 18 proprietary Chinese medicine preparations over a six-year period, and are currently working on the development of four new drugs that are mainly used to treat diabetes, cardiovascular and cerebrovascular diseases, and cranial nerve diseases. And insomnia and so on.
Yan Xijun said that the research and development of "component Chinese medicine" is based on the premise of adherence to the theory of traditional Chinese medicine, based on the resources of traditional Chinese medicine, and in accordance with the relevant laws and regulations of national drug development and examination and approval. It not only maintains the regularities and characteristics of compatibility of traditional Chinese medicine formulas, but also can achieve quality safety, clear composition, clear pharmacology, and also helps to enhance the international recognition of Chinese medicine and promote the internationalization of traditional Chinese medicine.
Bradley Keller, a congenital pediatric cardiologist at the Pittsburgh Children's Hospital in the United States, said in an interview: “Developing new drugs in known Chinese medicine resources is a smart exploration. Although Chinese medicine is mainly based on experience, China People's applications over the centuries constitute the best clinical practice."
Yan Xijun pointed out that the cost of research and development of new medicines through “component Chinese medicine†is likely to double the research and development costs of domestic proprietary Chinese medicines, but this route is still more economical than the development of new drugs in Europe and the United States.
According to statistics from the State Food and Drug Administration, 20 varieties of Chinese herbal medicines currently entered the catalogue of herbal medicines for plants in France, 7 standards for Chinese herbal medicines entered the French Pharmacopoeia, and 4 standards for Chinese herbal medicines entered the European Pharmacopoeia. China has maintained close cooperation in the traditional medicine field with the United States, Canada, France, the European Union, Italy, Australia, Singapore, Thailand and other countries and regions.